Almonertinib hydrochloride
Code | Size | Price |
---|
TAR-T5675-1mg | 1mg | £145.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T5675-5mg | 5mg | £227.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T5675-10mg | 10mg | £334.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T5675-25mg | 25mg | £524.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T5675-50mg | 50mg | £707.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
HS-10296 hydrochloride is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.
CAS:
2134096-03-8
Formula:
C30H36ClN7O2
Molecular Weight:
562.12
Pathway:
JAK/STAT signaling; Angiogenesis; Tyrosine Kinase/Adaptors
Purity:
0.9801
SMILES:
Cl.COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C2CC2)c2ccccc12
Target:
EGFR
References
Wu S G , Shih J Y . Management of acquired resistance to EGFR TKI?targeted therapy in advanced non-small cell lung cancer[J]. Molecular Cancer, 2018, 17(1):38.
Ivana S , David P . Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line[J]. Frontiers in Medicine, 2017, 3.